Publications by Year: 2004

2004

Vella, Monica C, Eun-Young Choi, Shin-Yi Lin, Kristy Reinert, and Frank J Slack. (2004) 2004. “The C. Elegans MicroRNA Let-7 Binds to Imperfect Let-7 Complementary Sites from the Lin-41 3’UTR”. Genes & Development 18 (2): 132-7.

Caenorhabditis elegans let-7, a founding member of the microRNA family, is predicted to bind to six sites in the 3'UTR of the mRNA of its target gene, lin-41, to down-regulate LIN-41. Here, we demonstrate that wild-type let-7 microRNA binds in vitro to RNA from the lin-41 3'UTR. This interaction is dependent on two conserved let-7 complementary sites (LCSs). A 27-nucleotide sequence between the LCSs is also necessary for down-regulation in vivo. LCS mutations compensatory to the lesion in let-7(n2853) can partially restore lin-41 3'UTR function in a let-7(n2853) background, providing the first experimental evidence for an animal miRNA binding directly to its validated target in vivo.

Vella, Monica C, Kristy Reinert, and Frank J Slack. (2004) 2004. “Architecture of a Validated MicroRNA::Target Interaction”. Chemistry & Biology 11 (12): 1619-23.

MicroRNAs are small approximately 22 nucleotide regulators of numerous biological processes and bind target gene messenger RNAs to control gene expression. The C. elegans microRNA let-7 and its target lin-41 were the first microRNA::target interaction to be validated in vivo. let-7 molecules form imperfect duplexes with two required let-7 complementary sites in the lin-41 3' UTR. Here, we show that base pairing at both the 5' and 3' ends of the let-7 binding site, as well as the presence of unpaired RNA residues in the predicted duplexes, are required for lin-41 downregulation. In this study, our model for microRNA::target interactions also demonstrates that the context of a microRNA binding can be critical for function, revealing an unforeseen complexity in microRNA::target interactions.

Esquela-Kerscher, Aurora, and Frank J Slack. (2004) 2004. “The Age of High-Throughput MicroRNA Profiling”. Nature Methods 1 (2): 106-7.